Royal Bank of Canada Buys 817,244 Shares of Cellebrite DI Ltd. $CLBT

Key Points

• Royal Bank of Canada significantly increased its stake in Cellebrite DI Ltd. by acquiring 817,244 shares, totaling 824,226 shares and representing 0.34% ownership worth approximately $16 million.
• Several other institutional investors also entered or expanded their positions in Cellebrite DI during the first quarter, contributing to 45.88% of the company's stock now being owned by hedge funds and institutional investors.
• Cellebrite DI reported earnings of $0.12 EPS, exceeding analyst expectations, with revenue of $113.28 million for the quarter, marking an 18.4% increase compared to the same quarter last year.

Royal Bank of Canada increased its position in Cellebrite DI Ltd. (NASDAQ:CLBT - Free Report) by 11,705.0% in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 824,226 shares of the company's stock after acquiring an additional 817,244 shares during the period. Royal Bank of Canada owned about 0.34% of Cellebrite DI worth $16,015,000 at the end of the most recent reporting period.

Several other large investors also recently modified their holdings of the company. Voss Capital LP grew its holdings in shares of Cellebrite DI by 18.6% in the first quarter. Voss Capital LP now owns 3,843,602 shares of the company's stock worth $74,681,000 after acquiring an additional 603,602 shares during the period. Invesco Ltd. grew its holdings in shares of Cellebrite DI by 122.1% in the first quarter. Invesco Ltd. now owns 3,296,079 shares of the company's stock worth $64,043,000 after acquiring an additional 1,811,757 shares during the period. T. Rowe Price Investment Management Inc. bought a new stake in shares of Cellebrite DI in the first quarter worth $60,939,000. Two Sigma Advisers LP grew its holdings in shares of Cellebrite DI by 35.0% in the fourth quarter. Two Sigma Advisers LP now owns 1,811,100 shares of the company's stock worth $39,899,000 after acquiring an additional 470,000 shares during the period. Finally, Handelsbanken Fonder AB grew its holdings in shares of Cellebrite DI by 749.9% in the first quarter. Handelsbanken Fonder AB now owns 1,518,700 shares of the company's stock worth $29,508,000 after acquiring an additional 1,340,000 shares during the period. Institutional investors own 45.88% of the company's stock.

Cellebrite DI Trading Down 2.2%

Shares of NASDAQ:CLBT traded down $0.38 during mid-day trading on Friday, reaching $16.80. The stock had a trading volume of 1,572,538 shares, compared to its average volume of 2,185,428. The company has a market cap of $4.02 billion, a P/E ratio of 50.53, a price-to-earnings-growth ratio of 3.12 and a beta of 1.28. Cellebrite DI Ltd. has a 1 year low of $13.10 and a 1 year high of $26.30. The business's 50 day moving average price is $15.18 and its 200 day moving average price is $16.97.

Cellebrite DI (NASDAQ:CLBT - Get Free Report) last posted its earnings results on Thursday, August 14th. The company reported $0.12 EPS for the quarter, topping analysts' consensus estimates of $0.11 by $0.01. The company had revenue of $113.28 million for the quarter, compared to the consensus estimate of $112.33 million. Cellebrite DI had a positive return on equity of 23.92% and a negative net margin of 34.56%.The firm's revenue for the quarter was up 18.4% on a year-over-year basis. During the same period in the previous year, the business earned $0.10 earnings per share. Cellebrite DI has set its Q3 2025 guidance at EPS. FY 2025 guidance at EPS. Analysts predict that Cellebrite DI Ltd. will post 0.3 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several analysts recently commented on the company. Lake Street Capital cut their price objective on Cellebrite DI from $24.00 to $22.00 and set a "buy" rating for the company in a report on Friday, August 15th. Needham & Company LLC lowered their target price on Cellebrite DI from $24.00 to $18.00 and set a "buy" rating on the stock in a research report on Thursday, August 14th. Finally, Wall Street Zen upgraded Cellebrite DI from a "hold" rating to a "buy" rating in a research report on Saturday, August 16th. Five investment analysts have rated the stock with a Buy rating, Based on data from MarketBeat, Cellebrite DI currently has an average rating of "Buy" and a consensus price target of $22.40.

Cellebrite DI Profile

Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.